CME Group Inc.

🇺🇸NASDAQ Global Select
Back to all articles
CME Group Inc. stock analysis CME overview
Bullish +65

KBW says buy the dip on CME Group shares, says perpetual futures fears are overblown

📈 KBW upgrades CME Group shares to 'outperform' from 'market perform' with a $305 price target implying 21% upside.

💰 The stock has declined nearly 8% year-to-date and 17% over the past month due to regulatory headwinds.

⚖️ CME Group plans to sue the CFTC regarding its approval of perpetual futures contracts, with CEO Terry Duffy confirming litigation will be filed tomorrow.

🛡️ KBW analyst Chris Allen argues perpetual futures fears are overblown for CME given its low retail exposure and index licenses in equities products.

📊 Of 17 analysts covering CME Group, 8 hold buy or strong buy ratings according to LSEG data.

📉 Perpetual futures contracts enable trading without holding assets and often feature massive leverage, posing general market risks.

🗣️ CEO Terry Duffy stated the company is 'not trying to pick a fight' but simply trying to 'state the law' in its legal challenge.

Bullish Signals
  • KBW upgraded CME Group shares to 'outperform' from 'market perform', signaling strong institutional confidence.
  • A $305 price target implies 21% upside potential from Wednesday's close, suggesting significant undervaluation.
  • The analyst notes that perceived perpetual futures risk is overblown for CME specifically due to low retail exposure and index licenses in equities products.
  • KBW views the recent downward acceleration as creating an attractive risk/reward profile for investors.
  • The bullish call aligns with Wall Street consensus, where 8 out of 17 analysts currently hold buy or strong buy ratings.
Risk Factors
  • CME Group shares have declined nearly 8% year-to-date and 17% over the past month due to regulatory friction.
  • The company is preparing to fight federal regulators in court regarding its bid to embrace perpetual futures contracts.
  • Perpetual futures contracts pose risks to investors and broader markets by enabling trading without holding assets and often boasting massive leverage.
  • CME Group's recent stock performance has been largely driven by the controversy surrounding its initiative to embrace perpetual futures.
Full Analysis
KBW analyst Chris Allen has upgraded CME Group shares to 'outperform' from 'market perform', citing an attractive risk/reward profile as the stock declines. The firm maintains a $305 price target, implying 21% upside from recent lows. KBW argues that fears surrounding perpetual futures are overblown for CME specifically due to its low retail exposure and index licenses in equities products. CME Group has dropped nearly 8% year-to-date and 17% over the past month, largely driven by regulatory friction regarding its bid to embrace perpetual futures contracts. The company plans to sue the Commodity Futures Trading Commission (CFTC) over the regulator's approval of these derivatives, which allow trading without holding assets and often involve massive leverage. CEO Terry Duffy stated the firm will file litigation tomorrow to 'state the law' rather than pick a fight. This bullish analyst call aligns with broader Wall Street consensus, with 8 out of 17 analysts covering the stock currently holding buy or strong buy ratings according to LSEG data. The article highlights that while perpetual futures pose risks to investors and markets generally, CME's specific business model mitigates these concerns compared to other exchanges. KBW views the recent downward acceleration in share price as a buying opportunity, suggesting that the regulatory battle and market overreaction have created a favorable entry point for investors looking at the exchange's long-term prospects.